cyclohexanol has been researched along with oxidopamine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le Fur, G; Poncelet, M; Rinaldi-Carmona, M; Soubrié, P; Souilhac, J | 1 |
| Anderson, JJ; Anderson, LA; Chase, TN; Walters, JR | 1 |
| Khen, S; Patrick, RL; Patrick, SL; Sañudo-Peña, MC; Tsou, K; Walker, JM | 1 |
| Sañudo-Peña, MC; Walker, JM | 1 |
| Bymaster, FP; Dreshfield-Ahmad, LJ; Hemrick-Luecke, SK; Nelson, DL; Shaw, JL; Thompson, L; Threlkeld, PG; Wong, DT | 1 |
| Baumann, B; Erlandsson, N; Giehl, KM; Kaufmann, K; Rössler, OG; Thiel, G; Wirth, T | 1 |
| Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B | 1 |
| Fernández-Ruiz, J; García, C; García-Arencibia, M; Palomo-Garo, C; Pertwee, R; Ramos, J | 1 |
8 other study(ies) available for cyclohexanol and oxidopamine
| Article | Year |
|---|---|
Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice.
Topics: Analgesics; Animals; Benzoxazines; Cannabis; Corpus Striatum; Cyclohexanols; Dose-Response Relationship, Drug; Female; Injections; Mice; Morpholines; Naphthalenes; Neurons; Oxidopamine; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Receptors, Neurokinin-2; Rimonabant; Stereoisomerism; Stereotyped Behavior | 1995 |
The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway.
Topics: Animals; Benzoxazines; Cannabinoids; Corpus Striatum; Cyclohexanols; Functional Laterality; Male; Morpholines; Motor Activity; Naphthalenes; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Drug; Rotation; Substantia Nigra | 1995 |
Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Cannabinoids; Corpus Striatum; Cyclohexanols; Globus Pallidus; Injections, Intraventricular; Male; Motor Activity; Neural Pathways; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1998 |
A novel neurotransmitter system involved in the control of motor behavior by the basal ganglia.
Topics: Action Potentials; Analgesics; Animals; Basal Ganglia; Benzoxazines; Bicuculline; Cannabinoids; Cyclohexanols; Dopamine; Dopamine Agonists; Electrophysiology; GABA Antagonists; gamma-Aminobutyric Acid; Morpholines; Motor Neurons; Naphthalenes; Nerve Degeneration; Neurotransmitter Agents; Oxidopamine; Piperidines; Pyrazoles; Quinpirole; Rats; Rimonabant; Sympatholytics; Thalamic Nuclei | 1998 |
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.
Topics: Animals; Biogenic Monoamines; Carrier Proteins; Cell Line; Cyclohexanols; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Monoamine Oxidase; Nerve Tissue Proteins; Neurons; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; p-Chloroamphetamine; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Sympatholytics; Symporters; Thiophenes; Venlafaxine Hydrochloride | 2001 |
Lack of correlation between NF-kappaB activation and induction of programmed cell death in PC12 pheochromocytoma cells treated with 6-hydroxydopamine or the cannabinoid receptor 1-agonist CP55,940.
Topics: Adrenergic Agents; Animals; Apoptosis; Cyclic AMP; Cyclohexanols; DNA-Binding Proteins; I-kappa B Proteins; Immunosuppressive Agents; NF-kappa B; NF-KappaB Inhibitor alpha; Oxidopamine; PC12 Cells; Pheochromocytoma; Rats; Receptors, Cannabinoid; Receptors, Drug; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2002 |
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid Receptor Modulators; Cerebellum; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fatty Acids, Unsaturated; Glutamic Acid; Glycerides; In Vitro Techniques; Levodopa; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Phospholipase D; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug | 2003 |
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
Topics: Animals; Antioxidants; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dopamine; Dronabinol; Glutamic Acid; Lipopolysaccharides; Male; Mice; Motor Activity; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |